1st World Congress on
Controversies in the Management of Viral Hepatitis (C-Hep)
Palau de Congressos de Catalunya, Barcelona, Spain, 19-22 May, 2011 |
|
| |
| Scientific Program |
 |
|
|
|
17:30-18:30 |
Opening Session |
|
|
17:30-17:35 |
Welcome Remarks |
|
|
17:35-17:40 |
Moderator: Rafael Esteban, Spain |
|
|
17:40-18:00 |
Honorary Opening Lecture: Who has Hepatitis C in 2011? Rafael Esteban, Spain |
|
|
18:00-18:20 |
Hepatitis B: Any controversies left? Greg Dore, Australia |
|
|
18:20-18:30 |
Discussion |
|
18:30-20:00 |
Welcome Reception |
|
|
08:30-10:00 |
Direct Antivirals: The Future is Now |
|
08:30-08:35 |
Chairpersons Welcome Address
Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel |
|
08:35-08:40 |
Overview of HCV sessions by HCV Program Director
Stefan Zeuzem, Germany
|
|
|
HCV Direct Acting Antivirals: |
|
08:40-08:45 |
Moderators: Stefan Zeuzem, Germany & Rafael Esteban, Spain |
|
08:45-09:05 |
What are they? Christoph Sarrazin, Germany |
|
|
09:05-09:25 |
Who needs them? David Nelson, USA |
|
|
09:25-09:45 |
How to use them? Paul Kwo, USA |
|
09:45-10:00 |
Discussion |
|
Hall A |
10:30-12:00 |
First Line Therapy: Are there preferred options? |
|
10:30-10:35 |
Moderators: Stefan Zeuzem, Germany & Rafael Esteban, Spain |
|
10:35-11:00 |
HCV Protease inhibitors: Overview of a new class of HCV drugs: Kenneth Sherman, USA
|
|
|
PEG-IFNα2a vs. PEG-IFNα2b vs. New Interferons |
|
|
11:00-11:15 |
PEG-IFNα2a: Stefan Zeuzem, Germany |
|
|
11:15-11:30 |
PEG-IFNα2b: Rafael Esteban, Spain |
|
|
11:30-11:45 |
New Interferons: Douglas Dieterich, USA |
|
|
11:45-12:00 |
Discussion |
|
|
Janssen Satellite Symposium
Why DAAs will Make a Difference: A New HCV Treatment Era |
| 12:00-12:05 |
Welcome and introduction
Xavier Forns, Spain |
| 12:05-12:20 |
Why DAAs will make a difference: efficacy and safety in treatment-naïve patients with HCV
Xavier Forns, Spain |
| 12:20-12:40 |
How will previously treated patients benefit in the new HCV treatment era?
Graham Foster, UK |
| 12:40-12:55 |
How will drug-drug interactions with DAAs affect patient management?
David Back, UK |
| 12:55-13:10 |
Does resistance matter? Understanding the mechanisms and implications
Christoph Sarrazin, Germany |
| 13:10-13:15 |
Summary and key learnings
Xavier Forns, Spain |
| 13:15 |
Meeting close |
|
|
14:00-15:00 |
Liver Biopsies: End of the Game? |
|
|
14:00-14:05 |
Moderator: Charles Boucher, The Netherlands |
|
|
14:05-14:25 |
New diagnostics for evaluating the liver, first line: Thierry Poynard, France |
|
|
14:25-14:45 |
New diagnostics for evaluating the virus: Jean Michel Pawlotsky, France |
|
14:45-15:00 |
Discussion |
|
|
15:00-16:00 |
Is there still a need for liver biopsies? |
|
|
15:00-15:05 |
Moderator: Ulrich Spengler, Germany
|
|
|
15:05-15:25 |
Yes: Kenneth Sherman, USA |
|
15:25-15:45 |
No: Thierry Poynard, France |
|
|
15:45-16:00 |
Discussion |
|
|
15:00-16:00 |
Does drug resistance testing have a clinical role in HCV therapy? |
|
|
15:00-15:05 |
Moderator: Jonathan Schapiro, Israel |
|
|
15:05-15:25 |
Pro: Charles Boucher, The Netherlands |
|
15:25-15:45 |
Con: Jean Michel Pawlotsky, France |
|
15:45-16:00 |
Discussion |
|
|
15:00-16:00 |
Frequent viral load monitoring: Necessity or Luxury? |
|
|
15:00-15:05 |
Moderator: Stefan Mauss, Germany
|
|
15:05-15:25 |
Necessity: Vicente Soriano, Spain |
|
|
15:25-15:45 |
Luxury: Hans Tillmann, USA |
|
15:45-16:00 |
Discussion |
|
16:00-16:15 |
Young Investigators Posters Award Ceremony
Sponsored by Roche |
|
|
16:30-17:30 |
Clinical Cases: Treatment of Hepatitis C: Case 1 |
|
|
Raffaele Bruno, Italy |
|
|
16:30-17:30 |
Clinical Cases: Treatment of Hepatitis C: Case 2 |
|
|
Lars Peters, Denmark |
|
|
16:30-17:30 |
Clinical Cases: Treatment of Hepatitis C: Case 3 |
|
|
Xavier Forns, Spain |
|
|
09:00-10:00 |
HIV/HCV Co-infected Patients: Time to treat or time to wait? |
|
09:00-09:05 |
Moderator: Marion Peters, USA |
|
09:00-09:25 |
Treat: Stefan Mauss, Germany |
|
09:25-09:45 |
|
|
09:45-10:00 |
Discussion |
|
|
09:00-10:00 |
Incorporating genetic markers into routine clinical care: Now or Later?
|
|
09:00-09:05 |
Moderator: Hans Tillmann, USA |
|
09:00-09:25 |
Now: Andri Rauch, Switzerland |
|
|
09:25-09:45 |
Later: Ulrich Spengler, Germany |
|
09:45-10:00 |
Discussion |
|
|
09:00-10:00 |
Acute Hepatitis C: What is new? |
|
09:00-09:15 |
Introduction and Moderator: Jürgen Rockstroh, Germany |
|
09:15-09:30 |
Do we need ribavirin for treatment of acute hepatitis C in HIV co-infected patients? |
|
09:30-09:45 |
Yes: Mark Nelson, UK |
|
|
09:30-09:45 |
No: Martin Vogel, Germany |
|
|
09:45-10:00 |
|
Plenary Session 11
Hall A |
10:30-12:00 |
HBV Therapy in 2011 |
|
10:30-10:35 |
Overview of HBV sessions by HBV Program Director: Fabien Zoulim, France |
|
|
10:35-10:40 |
Moderators: Fabien Zoulim, France & Maria Buti, Spain |
|
10:40-11:00 |
Hepatitis B therapy: Pietro Lampertico, Italy |
|
11:00-11:15 |
Is Hepatitis B curable? Fabien Zoulim, France
|
|
|
Interferon or oral anti-HBV drugs for first line therapy? |
|
11:15-11:30 |
Interferon: Patrick Marcellin, France |
|
11:30-11:45 |
Oral anti-HBV drugs: Maria Buti, Spain |
|
11:45-12:00 |
Discussion |
|
|
MSD Sponsored Satellite Symposium
Unlocking new possibilities in the treatment of HCV G1:
The Future of Direct Acting Antivirals
Chairman: Rafael Esteban-Mur, Spain |
| 12:00-12:05 |
Opening Remarks
Rafael Esteban Mur, Spain |
| 12:05-12:25 |
Emerging Clinical Data with New Direct Acting Antivirals
Rafael Esteban Mur, Spain |
| 12:25-12:45 |
Early predictors of response with new New Direct Acting Antivirals
Jean Michel Pawlotsky, France |
| 12:45-12:55 |
Optimizing Side Effect Management with New Direct Acting Antivirals
Michael Manns, Germany |
| 12:55-13:10 |
Panel Discussion – Q&A |
| 13:10-13:15 |
Closing Remarks
Rafael Esteban Mur, Spain |
Plenary Session 12
Hall A |
14:00-15:00 |
Clinical Cases: Hepatitis B
Supported by an unrestricted grant from Gilead Sciences
|
|
14:00-14:05 |
Moderator: Fabien Zoulim, France
|
|
14:05-14:20 |
Thomas Berg, Germany |
|
14:20-14:35 |
Maria Buti, Spain |
|
14:35-14:50 |
Geoffrey Dusheiko, UK |
|
14:50-16:00 |
Discussion |
|
|
15:00-16:00 |
Hot Topics in Viral Hepatitis |
|
15:00-15:05 |
Moderator: Douglas Dieterich, USA & Massimo Puoti, Italy |
|
15:05-15:20 |
Treatment of hepatitis Delta: Heiner Wedemeyer, Germany |
|
15:20-15:35 |
Silibinin rescue therapy: Thomas Berg, Germany |
|
15:35-16:00 |
Discussion |
|
|
"Pipeline Showcase"
Moderator: Jonathan Schapiro, Israel |
| 16:30-16:45 |
IDX184 and IDX375: Novel HCV Polymerase Inhibitors
Douglas L. Mayers, USA (Presentation supported by Idenix) |
| 16:45-17:00 |
Second generation Protease Inhibitor BI201335: promising clinical results in chronic
Hepatitis C
Tarik Asselah, France (Presentation supported by Boehringer Ingelheim) |
| 17:00-17:15 |
Hepatitis C: Drugs in Development at Abbott Laboratories
Barry Bernstein, USA (Presentation supported by Abbott) |
| 17:15-17:30 |
Potent Nucleotide Analogs in HCV: High Barrier to Resistance and Broad Genotype Activity
Patrick Marcellin, France (Presentation supported by Pharmasset) |
Plenary Session 14
Hall A |
09:00-10:00 |
Management of ESLD |
|
|
09:00-09:05 |
Moderators: Heiner Wedemeyer, Germany & Geoffrey Dusheiko, UK
|
|
|
09:05-09:25 |
Liver Transplantation in 2011: Marion Peters, USA |
|
09:25-09:45 |
Portal hypertension: State of the art: Ulrich Spengler, Germany |
|
09:45-10:00 |
Discussion
|
|
|
10:30-12:00 |
Beyond the Horizon |
|
|
10:30-10:35 |
Moderators: Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel
|
|
|
Can HCV be cured without interferon? |
|
10:35-10:55 |
Yes: Heiner Wedemeyer, Germany |
|
10:55-11:15 |
No: Geoffrey Dusheiko, UK |
|
11:15-11:30 |
Discussion
|
|
|
11:30-11:50 |
The Future is Now: Michael Manns, Germany |
|
11:50-12:00 |
Congress Chairpersons closure and summary
Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel |
|
|
|
|
WebStudio.co.il